

	<b>Health &amp; Wellbeing Board 14<sup>th</sup> July 2022</b>
<b>Title</b>	<b>Draft 2022 Pharmaceutical Needs Assessment</b>
<b>Report of</b>	<b>Tamara Djuretic – Director of Public Health</b>
<b>Wards</b>	<i>ALL.</i>
<b>Status</b>	Public
<b>Urgent</b>	No
<b>Key</b>	No
<b>Enclosures</b>	Draft Pharmaceutical Needs Assessment
<b>Officer Contact Details</b>	Tamara Djuretic – Director of Public Health – <a href="mailto:tamara.djuretic@barnet.gov.uk">tamara.djuretic@barnet.gov.uk</a> Jeremy Hooper – Insight & Intelligence Lead – Public Health – <a href="mailto:jeremy.hooper@barnet.gov.uk">jeremy.hooper@barnet.gov.uk</a>

## Summary

The publication of a Pharmaceutical Needs Assessment (PNA) is a statutory responsibility of all Health & Wellbeing Board's (HWBB). The HWBB has a responsibility to publish a new PNA every 3 years and in between updates revise the statement of the needs for pharmaceutical services if there are significant changes for the population in its area. As a result of the pandemic the deadline for publishing an updated PNA was extended to 1<sup>st</sup> October 2022.

A joint programme of work across the 5 Boroughs within North Central London ICB footprint. The production of the reports was tendered and Soar Beyond was commissioned to produce PNAs for all 5 Boroughs and we have been working to deliver the first draft which is now out to public consultation.

The HWBB in March delegated approval of the first draft to the DPH in consultation with the Chair of HWBB. The draft PNA was released for consultation on the 13<sup>th</sup> June and the consultation ends on the 12<sup>th</sup> August. The purpose of this paper is for information so members are provided a copy of the draft PNA and can submit feedback as part of the consultation process.

## Recommendations

- 1. That the Board note the production of the Draft PNA which is currently out to consultation and encourages members, stakeholders and others to review the draft document and submit comments as part of the consultation process.**
- 2. To formally delegate, the sign-off of the final PNA, to the Chair of the Health and Wellbeing Board and Director of Public Health.**

## **1. WHY THIS REPORT IS NEEDED**

- 1.1 The publication of a PNA is one of the statutory duties of the HWBB, this report gives members an opportunity to review the draft PNA to ensure they and other can contribute effectively to the ongoing public consultation.

## **2. REASONS FOR RECOMMENDATIONS**

- 2.1 Timelines for publication and meetings of the Board mean that delegation is required to allow the PNA to be published in line with the statutory obligations.

## **3. ALTERNATIVE OPTIONS CONSIDERED AND NOT RECOMMENDED**

- 3.1 None

## **4. POST DECISION IMPLEMENTATION**

- 4.1 The Chair and Director of Public Health will agree the final version of the PNA once it has been updated to reflect the feedback provided in the public consultation process which is ongoing.

## **5. IMPLICATIONS OF DECISION**

### **5.1 Corporate Priorities and Performance**

- 5.1.1 Not applicable.

### **5.2 Resources (Finance & Value for Money, Procurement, Staffing, IT, Property, Sustainability)**

Not Applicable

### **5.3 Social Value**

Social Value was considered in the tender process. Social Value is an integral part of a PNA to ensure that communities are able to access Pharmacies at times and locations which are convenient for the local population of an area.

### **5.4 Legal and Constitutional References**

- 5.4.1 Section 128A of the National Health Service Act 2006 (NHS Act 2006) requires each health and wellbeing board to assess the need for pharmaceutical services in its area and to publish a statement of its assessment. Termed a 'pharmaceutical needs assessment', the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013, as amended (the 2013 regulations) set out the minimum information that must be contained within a pharmaceutical needs assessment and outline the process that must be followed in its development.
- 5.4.2 At the end of March 2021, the Department of Health and Social Care (DHSC) announced that due to ongoing COVID-19 pressures across all sectors, the requirement to publish renewed Pharmaceutical Needs Assessments (PNAs) will be suspended until October 2022 – an extra six months. The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 were updated to reflect this.

5.4.3 To jointly assess the health and social care needs of the population with NHS commissioners, and use the findings of a Barnet Joint Strategic Needs Assessment (JSNA) to inform all relevant local strategies and policies across partnership.

**5.5 Risk Management**

Not Applicable

**5.6 Equalities and Diversity**

The PNA has been developed considering equality and diversity.

**5.7 Corporate Parenting**

Not Applicable

**5.8 Consultation and Engagement**

5.8.1 The consultation and engagement team have supported the development of the public consultation process, including ensure the document and consultation meets accessibility standards. They have also been involved in the review of early drafts of the document.

**5.9 Insight**

5.9.1 The Insight & Intelligence Team in collaboration with the Public Health Intelligence Teams in the other Boroughs of the NCL Footprint provided data to support the development of the needs assessment section.

**6. BACKGROUND PAPERS**

6.1 The public consultation was published on the 13<sup>th</sup> June 2022 on the Engage Barnet web portal (<https://engage.barnet.gov.uk/consultation-on-barnet-council-s-pharmaceutical-needs-assessment-2022>).

6.2 The draft PNA and a consultation Executive Summary are appendices.